COMPLETEDPHASE4

Patient Perception Study for AL-4943A

NCT01294969•Alcon Research

Summary

To evaluate patient perceptions of Al-4943 in subjects with allergic conjunctivitis previously treated with a topical ocular anti-allergy leukotriene-release inhibitor medication.

Eligibility

Age

12 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•History of allergic conjunctivitis within last 24 months
•Active signs and symptoms of ocular allergies

Exclusion Criteria

•Severe or serious ocular condition, ocular surgical intervention, ocular infection

Locations (1)

Alcon Korea Ltd.

Seoul, South Korea

Key Dates

Start Date

September 1, 2010

Primary Completion Date

October 1, 2011

Completion Date

October 1, 2011

Last Updated

December 16, 2016

Enrollment

47

ACTUAL participants

Conditions

Allergic Conjunctivitis

Interventions

AL-4943A

DRUG

The Role of Vitamin D in Corneal Epithelial Barrier Function, Ocular Microbiome, Ocular Inflammation, and Visual Acuity of Children With Allergic Conjunctivitis

NCT05839938

Allergic Conjunctivitis

View study

ACTIVE_NOT_RECRUITING

Tyrosine Allergoid Paediatric and Adult Study

NCT05186025

Allergic Rhinitis Due to PollenAllergic Conjunctivitis+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 16, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

COMPLETEDPHASE3